3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Multiple Myeloma
4
Recurrence
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Interventions
Dexamethasone
109
pomalidomide
53
Cyclophosphamide
52
Bortezomib
42
fludarabine phosphate
33
Lenalidomide
33
Peripheral Blood Stem Cell Transplantation
28
carfilzomib
26
Mycophenolic Acid
25
daratumumab
24
Calcium Dobesilate
24
Cyclosporine
22
Busulfan
21
Antilymphocyte Serum
20
Tacrolimus
19
Whole-Body Irradiation
18
Melphalan
17
Radiotherapy
15
Filgrastim
15
Methotrexate
14
fludarabine
12
Methylprednisolone
12
elotuzumab
11
Cord Blood Stem Cell Transplantation
11
selinexor
10
ixazomib
9
Etoposide
8
Thalidomide
7
Prednisone
7
Panobinostat
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
tanespimycin
×
Plasma cell
×
Clear all
NCT00113204
2008-05-20
IPi-504-01
Infinity Pharmaceuticals, Inc.
Phase 1
Completed
18 enrolled